328233-23-4

Basic information

• Product Name: trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid
• Synonyms: TRANS-1''-OXO-SPIRO[CYCLOHEXANE-1,3''(1''H)-FURO[3,4-C]PYRIDINE]-4-CARBOXYLIC ACID
• CAS NO: 328233-23-4
• Molecular Formula: C₁₃H₁₃NO₄
• Molecular Weight: 247.249
• Mol File: 328233-23-4.mol
• Article Data: 3

Chemical Properties

• Melting Point: 240-244 °C
• Boiling Point: 538.7 °C at 760 mmHg
• Flash Point: 279.6 °C
• Appearance: /
• Density: 1.41
• CAS DataBase Reference: trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid(328233-23-4)
• EPA Substance Registry System: trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid(328233-23-4)

Safety Data

• Hazardous Substances Data: 328233-23-4(Hazardous Substances Data)

Usage

General Description

Trans-1'-oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid is a complex organic compound with a spirocyclic structure. It is a carboxylic acid derivative, containing a spirocyclic system of fused cyclohexane and furo[3,4-c]pyridine rings. trans-1'-Oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid has the trans configuration, meaning that the substituents on the cyclohexane and furo[3,4-c]pyridine rings are in a trans relationship with each other. The presence of the carboxylic acid group makes this compound potentially useful in organic synthesis or as a building block for more complex molecules. Its unique spirocyclic structure may also give it interesting biological properties, making it potentially relevant in medicinal chemistry or drug development. Overall, trans-1'-oxo-spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid is a novel and intriguing chemical compound with potential applications in various fields.

Upstream product

• 3034-31-9 N-phenylisonicotinamide 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 328233-22-3 trans-3-oxo-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carbonitrile 
• 569351-62-8 1'-oxospiro[1,3'-cyclohexane(1'H)-furo[3,4-c]pyridine]-4-carboxylic acid 
• 870466-68-5 C₁₇H₂₁NO₄ 

Downstream Products

• 328232-95-7 MK-0557 
• 1195313-76-8 trans-3-oxo-N-(5-phenylpyridin-2-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 478014-55-0 trans-3-oxo-N-(2-phenyl-1,3-thiazol-4-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1195313-90-6 trans-N-[1-(3-fluorophenyl)-1H-pyrazol-3-yl]-3-oxo-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-93-5 trans-3-oxo-N-(1-phenyl-1H-pyrazol-3-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1195313-81-5 trans-3-oxo-N-(1-phenyl-1H-pyrazol-4-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-76-4 trans-3-oxo-N-(5-phenylpyrimidin-2-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-97-9 trans-3-oxo-N-(5-phenylisoxazol-3-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-99-1 trans-3-oxo-N-(2-phenyl-2H-1,2,3-triazol-4-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1195313-73-5 trans-3-oxo-N-(3-phenyl-1H-pyrazol-5-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 328232-94-6 trans-N-[1-(4-fluorophenyl)-1H-pyrazol-3-yl]-3-oxo-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1195313-71-3 trans-3-oxo-N-(5-phenylpyrazin-2-yl)-3H-spiro[6-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1192312-60-9 C₂₃H₁₉FN₄O₃ 
• 1192312-62-1 C₂₄H₂₁FN₄O₃ 

Relevant articles and documents

Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist

A series of trans-3-oxospiro[(aza)isobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide derivatives were synthesized to identify potent NPY Y5 receptor antagonists. Of the compounds, 21j showed high Y5 binding affinity, metabolic stability and brain and cerebrospinal fluid (CSF) penetration, and low susceptibility to P-glycoprotein transporters. Oral administration of 21j significantly inhibited the Y5 agonist-induced food intake in rats with a minimum effective dose of 1 mg/kg. This compound was selected for proof-of-concept studies in human clinical trials.

Practical synthesis of a neuropeptide Y antagonist via stereoselective addition to a ketene

The synthesis of neuropeptide Y antagonist 1, currently under clinical investigation for the treatment of obesity, is described. The convergent synthesis from trans-spirolactone carboxylic acid intermediate 2a and aminopyrazole 3 is predicated on a stereo